Second FDA OAI in two months for Aurobindo's Eugia unit

The U.S. FDA classified a second Aurobindo Pharma subsidiary facility as "official action indicated" (OAI) in two months. Eugia Pharma Specialities' formulation plant in IDA, Pashamylaram, near Hyderabad received the label Friday, the company disclosed in an exchange filing.

The regulator inspected the Unit-III site between January 27 and February 6. The inspection closed with 11 observations. OAI is the FDA's most severe post-inspection classification, signaling the agency is weighing regulatory or administrative action. The other two categories are No Action Indicated (NAI) and Voluntary Action Indicated (VAI).

Aurobindo said the classification will not affect the company's financials or operations. The statement reiterated a commitment to quality standards across all global facilities.

This follows the FDA's OAI ruling in May on another Eugia plant in Kolthur village, Ranga Reddy district. Two OAI designations at one subsidiary inside eight weeks shift the question from site-specific issues to broader oversight. Aurobindo's U.S. business, a major revenue driver, depends on FDA plant approvals for generic drug launches. Repeated flags at domestic facilities can slow new product clearances and invite heavier scrutiny on future inspections.

An OAI does not automatically trigger a warning letter, import ban, or consent decree. It puts the facility on an enforcement watchlist. The outcome depends on Aurobindo's remediation response and the FDA's next step, which typically comes as a warning letter or a request for reinspection.

The company is expected to detail corrective actions in its next earnings call. Investors will watch for any sign the FDA escalates enforcement beyond the two OAI labels.